Evidence map›Paper›PMID 33444292›Full record

ArticleThe Journal of clinical investigation2021

Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice.

Pirunthan Perampalam, Haider M Hassan, Grace E Lilly, Daniel T Passos, Joseph Torchia, Patti K Kiser, Andrea Bozovic, Vathany Kulasingam, Frederick A Dick

Open access · greenAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. The DREAM complex links somatic mutation, lifespan, and disease.bioRxiv : the preprint server for biology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Pirunthan PerampalamLondon Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
Haider M HassanLondon Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
Grace E LillyLondon Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
Daniel T PassosLondon Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
Joseph TorchiaLondon Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
Patti K KiserDepartment of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
Andrea BozovicDepartment of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada.
Vathany KulasingamDepartment of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada.
Frederick A DickLondon Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
Western University · CAUniversity Health Network · CA

Funding

CIHR MOP 324579
6 · The paper itself

Abstract

DREAM (Dp, Rb-like, E2F, and MuvB) is a transcriptional repressor complex that regulates cell proliferation, and its loss causes neonatal lethality in mice. To investigate DREAM function in adult mice, we used an assembly-defective p107 protein and conditional deletion of its redundant family member p130. In the absence of DREAM assembly, mice displayed shortened survival characterized by systemic amyloidosis but no evidence of excessive cellular proliferation. Amyloid deposits were found in the heart, liver, spleen, and kidneys but not the brain or bone marrow. Using laser-capture microdissection followed by mass spectrometry, we identified apolipoproteins as the most abundant components of amyloids. Intriguingly, apoA-IV was the most detected amyloidogenic protein in amyloid deposits, suggesting apoA-IV amyloidosis (AApoAIV). AApoAIV is a recently described form, whereby WT apoA-IV has been shown to predominate in amyloid plaques. We determined by ChIP that DREAM directly regulated Apoa4 and that the histone variant H2AZ was reduced from the Apoa4 gene body in DREAM's absence, leading to overexpression. Collectively, we describe a mechanism by which epigenetic misregulation causes apolipoprotein overexpression and amyloidosis, potentially explaining the origins of nongenetic amyloid subtypes.

Indexed as

AmyloidAnimalsApolipoproteins AImmunoglobulin Light-chain AmyloidosisMiceMice, KnockoutMultiprotein ComplexesOrgan SpecificityRetinoblastoma-Like Protein p107Amyloidapolipoprotein A-IVApolipoproteins AMultiprotein ComplexesRbl1 protein, mouseRetinoblastoma-Like Protein p107EpigeneticsLipoproteinsMouse modelsNephrologyVascular Biology

Identifiers

PMID33444292
PMCPMC7880409
OpenAlexW3120671396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.